Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis

Jun Aikawa 1, Kentaro Uchida 1*, Shotaro Takano 1, Gen Inoue 1, Dai Iwase 1, Masayuki Miyagi 1, Manabu Mukai 1, Shintaro Shoji 1, Hiroyuki Sekiguchi 2 and Masashi Takaso 1

Abstract

Background: The infrapatellar fat pad (IFP) is implicated in knee osteoarthritis (KOA). Calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide expressed in joint tissues and synovial tissues (ST), was recently found to be associated with KOA progression and pain. CGRP is expressed in the IFPs of human KOA patients; however, its regulation has not been elucidated.

Methods: IFPs and STs were harvested from 138 KOA patients during total knee replacement (TKR) and analyzed for CGRP, cyclooxygenase-2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) expression using real-time polymerase chain reaction (PCR). To investigate CGRP regulation by prostaglandin E2 (PGE2), adipocytes (Ad) and the stromal vascular fraction (SVF) were harvested from IFPs using collagenase. Synovial cells (SYC) were also harvested from ST and stimulated with vehicle (serum-free culture medium), PGE2, or CGRP.

Results: CGRP, COX-2, and mPGES-1 expression levels were significantly higher in IFPs than STs. PGE2 stimulation increased CGRP expression in Ad, the SVF, and SYC; however, CGRP expression was significantly higher in PGE2-stimulated SVF than PGE2-stimulated SYC. CGRP stimulation had no effect on COX-2 or mPGES-1 expression.

Conclusions: CGRP expression in the IFP of KOA patients is regulated by the COX-2/mPGES-1/PGE2 pathway.

Keywords: CGRP expression in the IFP of KOA patients is regulated by the COX-2/mPGES-1/PGE2 pathway.

Background

The infrapatellar fat pad (IFP) is located adjacent to the synovial tissue (ST). Several studies have suggested that factors produced in the IFP are linked to inflammation in the knee joint and could contribute to the development of knee osteoarthritis (KOA) [1, 2]. These factors have not yet been elucidated.

Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide. Several studies have linked elevated levels of CGRP in ST, the IFP, and joint capsule with the development and intensity of osteoarthritis (OA) pain [3–8]. For example, synovial CGRP expression is increased in patients with painful KOA [8]. We previously reported that CGRP is expressed in the IFP. Moreover, CGRP expression levels are correlated with OA grade [9]. These observations suggest that CGRP in the IFP may be a therapeutic target for KOA.

Previous studies have reported that CGRP expression in neural cells, synovial fibroblasts, and epithelial cells is regulated by inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and prostaglandin E2 (PGE2) [5, 10–12]. IFP also releases inflammatory mediators [13–15]. IFP produced interleukin-6 (IL-6) compared to subcutaneous adipose tissue (ScAT) [14]. Eymard et al. reported that the IFP releases higher levels of PGE2 than subcutaneous adipose tissue (ScAT) [13].
We previously reported a correlation between CGRP expression levels and COX-2 expression in the IFP of KOA patients [9]. CGRP expression in synovial fibroblasts is also regulated by the COX-2/PGE2 pathway.

We hypothesize that PGE2 regulates CGRP expression in the IFP. Here, we investigated CGRP regulation in the IFPs of KOA patients.

Methods
Harvesting IFP and ST samples
A sample size of 138 patients was deemed sufficient according to a power calculation using G*POWER3 (alpha = 0.05, power = 0.80). The study subjects included all patients who underwent primary TKA for OA in Kitasato University Hospital. The mean ± SD age of the patients was 73.0 ± 7.8 years, and the mean ± SD body mass index (BMI) was 26.2 ± 4.3 kg/m². The Kellgren-Lawrence (KL) grades among the patients were: KL2 = 3, KL3 = 53, and KL4 = 82 patients. This study protocol was approved by the Kitasato University Medical Ethics Organization (permission number KMEO B13–113). Each patient provided informed consent for participation in this study the day before surgery. IFPs and STs were harvested at the time of total knee replacement surgery. A portion of each IFP and ST sample was instantly frozen in liquid nitrogen and stored at −80 °C until RNA extraction.

Real-time polymerase chain reaction
We extracted total RNA and performed cDNA synthesis using ST and IFP samples according to our previously described method [9]. CGRP, COX-2, and mPGES-1 primers were based on previously designed primer sequences [9, 16]. Real-time polymerase chain reaction (RT-PCR) was performed as reported in our previous paper. mRNA expression of our genes of interest was normalized to that of glyceraldehyde dehydrogenase (GAPDH).

Isolation of synovial cells, the stromal vascular fraction, and adipocytes
To examine the regulation of CGRP expression by PGE2 in IFPs, the stromal vascular fraction (SVF) and adipocytes were extracted from IFPs from eight KOA patients. Adipocytes were isolated from IFPs using a modified version of a previously described method [15]. Briefly, IFP samples were ground up and digested in 1 mg/mL collagenase solution at 37 °C for 2 h with gentle agitation. The solution was filtered and centrifuged at 180 x g for 5 min. The floating top layer containing adipocytes was transferred into 25 cm² culture flasks (BD Falcon, Franklin Lakes NJ, USA) filled with Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad CA, USA) supplemented with 10% fetal bovine serum (FBS; Tissue Culture Biologicals, Long Beach CA, USA, Lot 106164) and incubated at 37 °C. During the incubation, cells floated up and attached to the upper inner surface of the flask. After 7 days, the medium was decanted and the flasks were inverted so that the adipocytes (Ad) were on the bottom. The floating top layer was collected and the remaining cells were centrifuged at 300 x g for 10 min to obtain the SVF. After suspension in culture medium, the SVF was transferred into 25 cm² culture flasks. Synovial cells were also harvested from same the patients as previously described. After culturing for 10 days, Ad, the SVF, and synovial cells were analyzed by RT-PCR to quantify the expression of adipocyte marker genes (adiponectin [Acrp30] and peroxisome proliferator-activated receptor [PPAR-γ]) [17], an endothelial marker (CD31) [18], and mesenchymal stem cell surface markers (CD90, CD105) [19]. Ad, SVF, and synovial cells were cultured with culture medium with or without 10 μM PGE2 (Cayman Chemical, Ann Arbor MI, USA), and CGRP expression was evaluated by RT-PCR. To evaluate the effect of CGRP on COX-2 and mPGES-1, Ad, SVF, and synovial cells were stimulated with culture medium with or without 100 nM CGRP (Sigma). PGE2 and CGRP concentrations were determined based on a previous study [5, 8, 20].

Results
CGRP, COX-2, and mPGES-1 mRNA expression in ST and IFPs. CGRP expression was significantly higher in IFPs than ST (2.0-fold, Fig. 1a). IFPs also exhibited significantly higher levels of COX-2 and mPGES-1 compared to ST (1.4-fold and 1.3-fold, respectively, p < 0.05; Fig. 1b, c).

CGRP expression in ad and SVF
RT-PCR showed that Acrp30 and PPAR-γ mRNA expression was significantly higher in Ad than the SVF and synovial cells (Fig. 2a, b). Expression of CD31, CD90, and CD105 was significantly higher in the SVF and synovial cells than in Ad (Fig. 2c–e). These results indicate that we successfully separated the SVF and Ad from IFPs. We subsequently analyzed the effects of PGE2 on CGRP mRNA expression in Ad, SVF, and synovial cells of OA patients by RT-PCR (Fig. 3). CGRP expression in the absence of PGE2 was significantly higher in Ad and the SVF than synovial cells (Fig. 3). Stimulation with PGE2 significantly increased CGRP expression in Ad, SVF, and synovial cells compared to vehicle controls. CGRP expression in PGE2-stimulated SVF was significantly higher than that in PGE2-stimulated synovial cells.
Effect of CGRP on COX-2 and mPGES-1 expression
To determine whether CGRP increases COX-2 and mPGES-1 expression, Ad, SVF, and synovial cells were cultured with CGRP. No differences were detected in COX-2 or mPGES-1 expression between CGRP-stimulated and vehicle control cells (Fig. 4a, b).

Discussion
The expression of CGRP, COX-2, and mPGES-1 was significantly higher in IFPs than ST. PGE2 stimulation increased CGRP expression in adipocytes, SVF, and synovial cells; however, CGRP expression in PGE2-stimulated SVF was significantly higher than that in PGE2-stimulated synovial cells. CGRP stimulation had no effect on COX-2 or mPGES-1 expression. Our results suggest that CGRP expression in the IFP in KOA is regulated by the COX-2/mPGES-1/PGE2 pathway.

Findings from previous studies indicate that CGRP expression in epithelial cells, synovial fibroblasts, macrophages, and T-cells is regulated by inflammatory...
mediators such as PGE2, TNF-α and IL-1β [5, 8, 10–12, 15, 21, 22]. We previously showed that CGRP expression in ST is correlated with the expression of COX-2 but not TNF-α and IL-1β, and that CGRP expression was increased in synovial fibroblasts following stimulation with PGE2 [5]. In addition, CGRP expression in IFPs is correlated with COX-2 expression [9]. Here, we demonstrated that the IFP expressed higher levels of CGRP and the PGE2-forming enzymes COX-2 (conversion of arachidonic acid to PGH2) and mPGES-1 (conversion of COX-2 derived to PGH2 to PGE2) compared to ST. In addition, CGRP expression in adipocytes and the SVF was stimulated by exogenous PGE2. Notably, PGE2-stimulated SVF had higher expression than that in synovial cells. Our findings suggest that COX-2 produced in the IFP, in particular the SVF, may be the source of CGRP in OA, and that CGRP expression in the IFP is regulated by the COX-2/mPGES-1 pathway.

Previous studies have shown that CGRP is expressed in several joint tissues such as the meniscus, joint capsule, ST, and IFP, and suggest that CGRP plays an important role in KOA progression, inflammation, or pain [3–8]. PGE2 is also considered to be a key mediator of inflammatory pain in OA. Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, constitute the main treatment option for pain in OA [23, 24]. mPGES-1 is expressed during inflammation and, according to mouse gene deletion studies, plays a critical role in inflammatory pain, suggesting that it may be an alternative therapeutic target for pain in KOA [25, 26]. Together, our findings and previous studies suggest that the COX-2/mPGES-1/PGE2/CGRP pathway may have an important role in OA pathophysiology.

There are two limitations of the present study. First, we did not examine a non-KOA patient group. Future studies should examine whether CGRP levels are higher in the IFPs of OA patients compared to normal subjects. Second, although CGRP levels were elevated in IFPs compared to that in STs, the relationship between CGRP and KOA pathology remains to be determined.
Conclusion
CGRP expression in the IFP of KOA patients is regulated by the COX-2/mPGES-1/PGE2 pathway. Further investigations may reveal more details of the pathophysiology and suggest additional therapeutic targets for KOA.

Abbreviations
AcPR3A: Adiponectin; CGRP: Calcitonin gene-related peptide; COX-2: Cyclooxygenase-2; IFP: Infrapatellar fat pad; IL-1β: Interleukin-1β; IL-6: Interleukin-6; KOA: Knee osteoarthritis; mPGES-1: Microsomal prostaglandin E synthase-1; NSAIDs: Non-steroidal anti-inflammatory drugs; PCR: Polymerase chain reaction; PGE-2: Prostaglandin E2; PPARγ: Peroxisome proliferator-activated receptor; ScAT: Subcutaneous adipose tissue; ST: Synovial tissues; SVF: Stromal vascular fraction; TKR: Total knee replacement; TNF-α: Tumor necrosis factor-α

Acknowledgements
We thank Ms. Yuko Onuki for assistance with the PCR analysis. We thank Libby Cone, MD, MA, from DMC Corp. (http://dmed.co.jp/) for editing drafts of this manuscript.

Funding
This study was supported in part by JSPS KAKENHI Grant no. 17 K16700, the Uehara Memorial Foundation, a Kitasato University Research Grant for Young Researchers, a research grant for Young Physicians and Health Professionals from SRL Inc., and research grants from the Parents’ Association of Kitasato University School of Medicine.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions
All authors provided intellectual contributions to the manuscript and read and approved the final version. For experimental design: KU and MT; for acquisition of data: JA, KU, ST, DI, MM (Miaygi), MM, (Mukai), SS, HS, and MM; for analysis and interpretation of data: JA, KU, HS, and MT For drafting of the manuscript: KU and MT.

Ethics approval and consent to participate
This study was approved by the Ethics Review Board of Kitasato University for analysis and interpretation of data: JA, KU, HS, and MT; for drafting of the manuscript: KU and MT.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Sagamihara City, Kanagawa 252-0374, Japan.
2Shonan University of Medical Sciences Research Institute, Nishikubo 500, Chigasaki City, Kanagawa 253-0083, Japan.

Received: 10 August 2018 Accepted: 4 September 2018

Published online: 11 September 2018

References
1. Jacobson JA, Lenchick L, Ruhoy MK, Schweitzer ME, Resnick D. MR imaging of the infrapatellar fat pad of Hoffa. Radiographics. 1997;17(3):675–91.
2. Vahleiebeck M, Linneborg G, Schild H, Schmidt HM. Hoffa’s recess: incidence, morphology and differential diagnosis of the globular-shaped cleft in the infrapatellar fat pad of the knee on MRI and cadaver dissections. Eur Radiol. 2002;12(1):90–3.
3. Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis. 2011;70(3):S23–9.
4. Dong T, Chang H, Zhang F, Chen W, Zhu Y, Wu T, Zhang Y. Calcitonin gene-related peptide can be selected as a predictive biomarker on progression and prognosis of knee osteoarthritis. Int Orthop. 2015;39(6):1237–43.
5. Minatani A, Uchida K, Inoue G, Takano S, Aikawa J, Miyagi M, Fujimaki H, Iwase D, Onuma K, Matsumoto T, Takaso M. Activation of calcitonin gene-related peptide signaling through the prostaglandin E2 EP1/EP2 EP4 receptor pathway in synovium of knee osteoarthritis patients. J Orthop Surg Res. 2016;11(1):117.
6. Saito T, Koshino T. Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin Orthop Relat Res. 2000;376:172–82.
7. Saxler G, Loer F, Skumavc M, Pfitzner J, Hanesch U. Localization of SP- and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties. Eur J Pain. 2007;11(4):675–74.
8. Takano S, Uchida K, Inoue G, Minatani A, Miyagi M, Aikawa J, Iwase D, Onuma K, Mukai M, Takaso M. Increase and regulation of synovial calcitonin gene-related peptide expression in patients with painful knee osteoarthritis. J Pain Res. 2017;10:1099–104.
9. Aikawa J, Uchida K, Takano S, Inoue G, Minatani A, Miyagi M, Iwase D, Sekiguchi H, Mukai M, Takaso M. Expression of calcitonin gene-related peptide in the infrapatellar fat pad in knee osteoarthritis patients. J Orthop Surg Res. 2017;12(1):65.
10. Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL. Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 2006;96(1):65–77.
11. Li W, Hou L, Hua Z, Wang X. Interleukin-1beta induces beta-calcitonin gene-related peptide secretion in human type II alveolar epithelial cells. FASEB J. 2004;18(13):1603–5.
12. Neeb L, Hellen P, Boehnike C, Hoffmann J, Schuh-Hofer S, Dimargi U, Reuter U. IL-1β stimulates COX-2 dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells. PLoCS One. 2016(13):e17360.
13. Gmyard F, Pigenet A, Citadelle D, Flouzat-Lachaniette CH, Poignard A, Benelli C, Berenbaum F, Chevalier X, Houard X. Induction of an inflammatory and prodegradative phenotype in autologous fibroblast-like synoviocytes by the infrapatellar fat pad from patients with knee osteoarthritis. Arthritis Rheumatol. 2014;66(8):2165–74.
14. Distel E, Cadouldal T, Durant S, Poignard A, Chevalier X, Benelli C. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 2009;60(11):3374–7.
15. Klein-Wieringa IR, Kloppenburg M, Bastaansen-Jenniskens YM, Yufut E, Kwekkeboom JC, El-Bannoudi H, Nelsissen RG, Zuurmond A, Stojanovic-Suslic V, Van Osch GJ, Toes RE, Iban-Facsinay A. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Arthritis Rheumatol. 2017;69(5):851–7.
16. Uchida K, Takano S, Matsumoto T, Nagura N, Inoue G, Ikatake M, Miyagi M, Aikawa J, Iwase D, Minatani A, Fujimaki H, Takaso M. Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-alpha stimulation of synovial cells: an in vitro study. BMC Musculoskelet Disord. 2017(18:1):283.
17. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167–75.
18. Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Peault B, Rubin JP, Donnenberg AD. Stromal vascular progenitors in adult human adipose tissue. Cytotherapy. 2010;12(7):22–30.
19. Chung MT, Liu C, Hyun JS, Lo DD, Montoro DT, Hasegawa M, Li S, Sorokin M, Rennert R, Keeney M, Yang F, Quarto N, Longaker MT, Wan DC. CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose-derived stromal cells. Tissue Eng Part A. 2013;19(7–8):989–97.
20. Wang H, Zhang X, He JY, Zheng XF, Li D, Li Z, Zhu JF, Shen C, Cai GQ, Chen XD. Increasing expression of substance P and calcitonin gene-related peptide in synovial tissue and fluid contribute to the progress of arthritis in developmental dysplasia of the hip. Arthritis Res Ther. 2015;17;4.
21. Bracci-Laudiero L, Aloe L, Buanne P, Finn A, Stenfors C, Vigneti E, Theodorsson E, Lundeberg T. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol. 2002;123(1-2):58–65.

22. Ma W, Dumont Y, Vercauteren F, Quirion R. Lipopolysaccharide induces calcitonin gene-related peptide in the RAW264.7 macrophage cell line. Immunology. 2010;130(3):399–409.

23. Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. ClinTher. 2011;33(12):1914–31.

24. da Costa BR, Reichenbach S, Keller N, Narrey L, Wandel S, Juni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e213–33.

25. Dray A, Read SJ. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther. 2007;9(3):212.

26. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtman TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase ProcNatlAcadSciUSA. 2003;100(15):9044–9.